The Year in Biotech So Far and What’s Ahead

FromThe Bio Report

Start listening View podcast show

The Year in Biotech So Far and What’s Ahead

FromThe Bio Report

ratings:

Length:

22 minutes

Released:

Aug 28, 2014

Format:

Podcast episode

Description

The biotech sector surged in the first half of the year despite volatile markets. M&A and financing continued to be robust as EvaluatePharma weighed in with its Pharma & Biotech Half-Year Report. We spoke to Jonathan Gardner, deputy news editor of EP Vantage, about the trends in the first half of the year, whether 2014 will set new records for M&A activity, and the threats out there that may put an end to the good times.

Released:

Aug 28, 2014

Format:

Podcast episode

Titles in the series (100)

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Skip carousel

The Forces Bringing Disruptive Change to Healthcare: Scientific breakthroughs, innovations in technology, and the changing use of data are among the forces that are driving disruptive changes to healthcare. A new report from the IMS Institute for Healthcare Informatics highlights a number of these deve... by The Bio Report
21 min listen
How New Funding Models Are Accelerating Drug Development: News last month of the Cystic Fibrosis Foundation’s $3.3 billion sale of royalty rights to Kalydeco and other Vertex Pharmaceuticals drugs it helped fund served as a bold statement to the growing prominence and power of venture philanthropy. We spok... by The Bio Report
18 min listen
Enlisting Monoclonal Antibodies to Combat Bacterial Resistance: There’s growing global concern about threat from antibiotic resistant pathogens. That’s leading to new interest in looking beyond traditional antibiotics to monoclonal antibodies to address the problem. We spoke to Ken Stover, senior director of infe... by The Bio Report
21 min listen
The Year in Biotech So Far and What’s Ahead: The biotech sector surged in the first half of the year despite volatile markets. M&A and financing continued to be robust as EvaluatePharma weighed in with its Pharma & Biotech Half-Year Report. We spoke to Jonathan Gardner, deputy news editor of EP... by The Bio Report
22 min listen
Epirus Sees Opportunities for Biosimilars Outside U.S.: The regulatory pathway for biosimilars is still a work in progress at the U.S. Food and Drug Administration, but around the world the industry is growing as regulators have resolved issues that remain obstacles in the United States. We spoke to Amit ... by The Bio Report
18 min listen
What’s Driving the Booming Market for Orphan Drugs: The market for Orphan drugs is growing at more than twice the rate of other prescription medicines In 2013, a record 260 therapeutics won orphan designations in the United States alone as science, policy, and pricing are fueling the trend for drugmak... by The Bio Report
18 min listen
The Lean Startup Takes Hold in the Life Sciences: The National Science Foundation and the National Institutes of Health, concerned about seeing the science they fund commercialized, have embraced the Lean Startup method as a way to improve the odds of success for new companies. Steve Blank, whose wo... by The Bio Report
23 min listen
Home-Brew Morphine, Dual Use Technology, and the Biologist’s Repsonsibilities: A recent article in Nature Chemical Biology that shows it is possible to convert sugar into morphine with genetically engineered yeast has sparked public attention over the potential illicit use of the technology and the need for regulation. The work... by The Bio Report
20 min listen
Reengineering Drug Discovery and Development: Drugmakers have employed new technologies to reduce the cost and time and it takes develop drugs and produce therapies that more precisely target the underlying biology driving diseases. Boston-based Berg Pharma is using artificial intelligence with ... by The Bio Report
21 min listen
Using Human Biology to Improve R&D: One problem with drug discovery and development is that answers about the way substances act in the human body are often not apparent early in the process. Though human cell assays have been used, they have their limitations. BioSeek’s BioMap technol... by The Bio Report
28 min listen
Will Increased FDA Regulation of Diagnostics Speed or Slow Development of Personalized Medicine: The U.S. Food and Drug Administration is moving to expand its regulatory domain by adding oversight of certain diagnostics it does not regulate today. The agency says thousands of these test are used daily to guide treatment decisions and diagnose di... by The Bio Report
27 min listen
Why Interoperability Is Much More than a Technology Problem: A new government report finds that healthcare providers in the United States are increasing their adoption of health information technology, but their willingness to do so is tied to the incentives available. What’s more, the government is implementi... by The Bio Report
26 min listen
How One Foundation is Getting the Biggest Bang for Its R&D Bucks: As pressure on government and corporate research budgets grow, organizations like the Multiple Myeloma Research Foundation are playing an increasingly critical role in advancing and accelerating drug development. The foundation’s efforts, including i... by The Bio Report
28 min listen
Telemedicine Grows, but Reimbursement Remains an Obstacle: While many may think of telemedicine as an example of digital health technologies that will reshape the future landscape of medicine, a new survey from the law firm Foley & Lardner shows it is very much part of healthcare’s here and now. We spoke to ... by The Bio Report
22 min listen
International Collaboration Seeks to Drive Breakthroughs in Progressive MS: There has been dramatic progress in the understanding and treatment of relapsing remitting multiple sclerosis, a debilitating neurodegenerative disorder. But progressive MS, a more advanced form of the disease, has remained elusive. Now, a novel coll... by The Bio Report
24 min listen
A Look at the Year That Was in Biotech: The year 2014 was one for the record books for the biotech industry. In part one of a two-part podcast, we take a look back at the year that was with Adam Feuerstein, senior columnist for TheStreet.com. Feuerstein discusses the growing controversy ov... by The Bio Report
15 min listen
The Power of IBM’s Watson Is Coming to an App Near You: IBM’s Watson Group recently announced an investment in Pathway Genomics, part of a $100 million initiative by the computing giant to spur innovation in entrepreneurial companies that seek to leverage its cognitive computing platform Watson. Pathway G... by The Bio Report
18 min listen
Remembering Industry Pioneer Ron Cape by The Bio Report
27 min listen
Weighing Adverse Events to Get at a Drug’s Real Costs: Adverse events from drugs cost the U.S. healthcare system an estimated $25 billion in 2013, but data from adverse events reporting is generally not factored into payer and provider decisions about what drugs are most cost-effective. The healthcare an... by The Bio Report
17 min listen
Calculating the Cost of Drug Development and What it Means: The cost of drug development, a metric that underlies discussions ranging from investment in startups to drug pricing, is a matter of great interest and controversy within the pharmaceutical industry. The Tufts Center for the Study of Drug Developmen... by The Bio Report
20 min listen
TheStreet’s Adam Feuerstein Previews ASCO 2015: Wall Street’s attention will turn to Chicago as the annual meeting of the American Society of Clinical Oncology runs from May 29 to June 2. Some 5,000 abstracts became available mid-month and investors have been sifting through them to gain insights ... by The Bio Report
14 min listen
Understanding the Cost and Value of Cancer Therapies: The National Comprehensive Cancer Network in October will release a new tool designed to help doctors understand the value of different cancer therapies by taking into account the costs of treatments. The effort from the influential group follows sim... by The Bio Report
22 min listen
Why Patent Trolling Threatens Biopharma: The biopharmaceutical industry has long been considered immune to the threat of patent trolls, patent holders who seek to monetize the value of a patent through enforcement rather than productive use. But a paper by UC Hastings Robin Feldman and Harv... by The Bio Report
16 min listen
Brittany Maynard and the Debate over the Right to Die: Brittany Maynard, a 29-year-old woman with terminal brain cancer who chose to end her own life with a lethal dose of medication, sparked a renewed discussion of so-called death with dignity laws. Maynard had become visible on social and traditional m... by The Bio Report
23 min listen
Why Big Pharma Hasn’t Been Able to Fix Its Revenue Gap with M&A by The Bio Report
17 min listen
Reinventing Tech Transfer: Universities are moving away from a passive approach to technology transfer to engage with industry in new partnerships, put a greater emphasis on translational research, and nurturing technologies so they can give rise to new products and companies.... by The Bio Report
21 min listen
Thinking Narrowly About Antibiotics: With the mapping of the human microbiome, a new understanding is emerging of the complex relationship between the microorganisms that live in the human gut, skin, and elsewhere on the body, and the role they play both in disease and in maintaining he... by The Bio Report
24 min listen
What a Decade of Investment Tells Us about the Health of Biotech: A detailed view of funding of emerging therapeutic companies over the past ten years shows despite a rebound in venture financing, companies continue to struggle to find early-stage money. Nevertheless, the report shows the overall health of investme... by The Bio Report
14 min listen
How the Sugar Industry Influenced Research to Protect Its Interests: A newly discovered archive of documents reveal the sugar industry’s efforts to shape the national research agenda away from the effects of sugar on tooth decay and push for programs to focus on alternatives to reducing consumption. We spoke to Cristi... by The Bio Report
13 min listen
Innovative Drugs Drive Big Increase in U.S. Spending: In April, the IMS Institute released a new report that U.S. drug spending in 2014 rose 13.1 percent to $373.9 billion, the largest single year increase in spending since 2001. A number of factors drove the increase including the launch of innovative ... by The Bio Report
20 min listen

More Episodes from The Bio Report

Skip carousel

Overcoming Resistance in Cancer with Chemistry: Kinase inhibitors have given rise to an era of precision medicine for the treatment of cancer, but the ability of cancer cells to mutate enables tumors to develop resistance to existing therapies. Nuvalent is developing therapies that both target the... by The Bio Report
30 min listen
Teaching an Old Drug a New Trick to Prevent Lyme Disease: Each year, an estimated 400,000 people in the United States will be diagnosed with Lyme disease, a billion-dollar healthcare problem caused by a bacterial infection that is transmitted through the bite of a tick. The condition can cause joint pain an... by The Bio Report
20 min listen
A New Class of Cell Therapies to Target Solid Tumors: In February, the U.S. Food and Drug Administration approved the first tumor-infiltrating lymphocyte, or TIL therapy, for solid tumors. The approval was hailed as a milestone that points the path forward for a new class of cell therapies for solid tum... by The Bio Report
33 min listen
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies: Lipids have long been used as drug delivery vehicles, but HighField Biopharmaceutics is repurposing lipids as drugs to fight cancer. The company’s technology platform is seeking to change the immunotherapy landscape with new treatments that are bette... by The Bio Report
35 min listen
A Company Born from a Father Who Wore His Heart on His Sleeve: Jeremiah Robison’s daughter Sofia was born with cerebral palsy, a congenital movement disorder. Watching her physicians use body monitors to measure her gait, and later apply functional electrical stimulation as physical therapy, gave him an idea to ... by The Bio Report
32 min listen
Using AI to Improve Burn Care: Physicians treating people with burns typically incorrectly assess the depth of burn wounds in about 25 to 30 percent of cases. That, in part, is due to a lack of diagnostic tools to assess the severity of a burn and to determine the best approach to... by The Bio Report
24 min listen
A Home for Biotech in the City that Never Sleeps: New York City is not the first place that comes to mind when thinking of biotech clusters, but the Big Apple has been a growing center of biomedical innovation with its mix of academic research hospitals, finance, and growing number of biopharmaceuti... by The Bio Report
33 min listen
Biopharma R&D Growing Stronger: Funding levels, drug launches, and R&D success rates all grew in 2023, according to a new report from the IQVIA Institute for Human Data Science. Global funding of biopharmaceutical research and development increased to $72 billion, up from $61 b... by The Bio Report
31 min listen
The Benefits of Having a Multitude of Cins: In January 2023, AstraZeneca agreed to acquire CinCor Pharma, the CinRx cardio-renal disease therapy subsidiary, for $1.3 billion. The deal included a potential additional $500 million milestone payment. The price represented a 121 percent premium to... by The Bio Report
33 min listen
Making ADCs Smarter and Safer with a Simple Twist of Fate: Antibody-drug conjugates can deliver chemotherapy directly to tumors but more than 95 percent of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity. Mythic Therapeutics FateControl technology improves the uptake of... by The Bio Report
24 min listen
Targeting a Natural Repair System to Restore Brain Health: The HGF/MET neurotrophic system plays a critical role in the maintenance and repair of connections in the brain. Enhanced signaling along this pathway has the potential to reduce inflammation, slow neurodegeneration, and provide neuroprotection. Athi... by The Bio Report
19 min listen
Programing Cells in a Predictable and Scalable Way: The advent of induced pluripotent stem cells, cells that can be coaxed into becoming virtually any type of cell within the body, promised to usher in a new era of regenerative medicine and improved drug discovery. In practice, though, the ability to ... by The Bio Report
32 min listen
Why DNA May Be the Data Storage Medium of the Future: Some 100 trillion gigabytes of data are created and consumed each year, an amount that is expected to double by 2025. The demand for data storage carries the need for significant physical space and power requirements in the form of digital data cente... by The Bio Report
32 min listen
Scouring Genetic Variation within Our Cells for Drug Targets: People tend to think of each person having their own unique genome. Quotient Therapeutics is taking an approach to drug discovery based on the reality that from cell to cell within a given individual, there can be trillions of divergent genomes. Chan... by The Bio Report
26 min listen
Correcting Gene Dysregulation to Treat Diseases: Regardless of the cause of a disease, most diseases involve gene dysregulation. Omega Therapeutics is developing a new class of programmable, epigenomic, mRNA medicines designed to make specific epigenetic changes and correct abnormal gene expression... by The Bio Report
45 min listen
Using Technology to Regain Abilities after Spinal Cord Injury: The effects of spinal cord injury extend beyond the loss of mobility. They can include a toll on mental health, a feeling of exclusion, and a general decline in the quality of life as a result of being able to stand and interact eye-to-eye with other... by The Bio Report
25 min listen
Why Drug Developers Have a Growing Interest in Targeting Mitochondria: Mitochondria are often referred to as the “powerhouses” of the cell, but as scientists gain a greater understanding of these essential organelles, they are coming to discover they play a more expansive role in health and disease. The Foundation for t... by The Bio Report
39 min listen
Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates: Sandbox AQ, the Alphabet spin-out backed with $500 million in investment, in June 2023 unveiled it AQBioSim division. The division is working to bring SandoxAQ’s AI and quantum-inspired computing to develop new treatments for intractable medical cond... by The Bio Report
32 min listen
Targeting a Multitude of CIN in Cancer Cells: It’s long been understood that chromosomal instability (CIN) is a characteristic of cancer cells, but it also represents a key difference between cancer cells and healthy cells that can be exploited. Volastra is developing medicines for a wide range ... by The Bio Report
21 min listen
The Year in Biotech and What’s Ahead in 2024: Though the year began with a banking crisis and has been marked with layoffs and restructurings, we have managed to avoid a feared recession. It’s been a big year for new drug approvals, M&A activity has been brisk, and biotech stocks have rallie... by The Bio Report
33 min listen
Transforming Healthcare with Data: Vik Bajaj has long lived at the intersection of physical sciences, engineering, data science, and the life sciences—first as an academic working to improve diagnostic imaging at Stanford University and later as a chief scientific officer at GRAIL and... by The Bio Report
51 min listen
Realizing the Promise of IL-2 Therapies with AI: Interleukin-2 therapies have been seen as promising ways to treat solid tumors, but they have proven challenging because of the ability of IL-2 to both activate and suppress the immune system. Their effectiveness has been limited because of potential... by The Bio Report
23 min listen
Unlocking Real-World Data to Improve Outcomes: Real-world data promises to provide insights that lead to better therapies, change how we treat diseases, and improve outcomes for patients. One of the limits of realizing benefits from all of the health information we are swimming in is the lack of ... by The Bio Report
40 min listen
A Silicon Valley Entrepreneur Investing at the Intersection of Tech and Biotech: Artificial intelligence promises to reshape the healthcare landscape and deliver new insights into the molecular drivers of health and wellness, provide rapid diagnoses of patients, and discover and design therapies that extend beyond human imaginati... by The Bio Report
25 min listen
A Company Betting Its Physics-Based AI Will Fuel a Quantum Leap in Drug Discovery: Though many drug developers are harnessing AI to create novel chemical compounds, Iambic Therapeutic’s generative AI is leveraging quantum mechanics to get to better drugs. It says its physics-informed machine learning approach has yielded promising ... by The Bio Report
24 min listen
Detecting Alzheimer’s Disease Early through a Blood Test: One of the challenges with treating Alzheimer’s disease is diagnosing patients early enough in the course of its progression to have a meaningful impact with treatments. Sunbird Bio said it can accurately detect and differentiate specific proteins th... by The Bio Report
25 min listen
Addressing Supply-Chain Challenges Underlying Drug Shortages with Synthetic Biology: About 40 percent of all drugs in the Western world are derived from plants. But challenges with producing a reliable supply inherent with materials derived from agricultural processes can lead to drug shortages as climate events, pests, and plant dis... by The Bio Report
28 min listen
Building Better and More Affordable Vaccines: The COVID 19 pandemic provided a painful reminder of the global need to protect people against the threat of existing and emerging infectious diseases. Emergex Vaccines is developing fully synthetic vaccines that provide advantages over live attenuat... by The Bio Report
42 min listen
Overcoming Resistance to Targeted Therapies: The advent of targeted therapies has contributed to notable progress in the fight against cancer, but the ability of cancers to develop resistance to these precision medicines continues to leave patients in need of new approaches. Concarlo Therapeuti... by The Bio Report
30 min listen
Using Tumor Gene Therapy to Overcome Barriers to Immunotherapies: There have been significant advances to immunotherapies since their first introduction, but challenges remain to realizing their full potential in solid tumors. That’s because of the ability of tumors to use multiple mechanisms to evade the immune sy... by The Bio Report
30 min listen

Related podcast episodes

Skip carousel

As biopharma deals keep pace, M&A volumes languish by The BioWorld Insider Podcast
14 min listen
The Outlook for Biotech in 2018: We conclude our biotech review-preview series with our final installment this week as we take a look at the year ahead as the industry readies for the JPMorgan Healthcare Conference. We spoke to Jon Gardner, U.S. News Editor for EP Vantage, about the... by The Bio Report
20 min listen
Reviving the stagnant plant based meat market: After a record run of growth, why did plant-based meat sales decline in the U.S.? And what would it take to turn things around? by Catalyst with Shayle Kann
41 min listen
A Rich Pipeline Expected to Drive Industry’s Growth: Evaluate Pharma, in its latest World Preview report, is projecting solid growth for prescription drug sales through 2022. Driving that growth is both the new products expected to come to market during that time and the industry’s embrace of orphan dr... by The Bio Report
19 min listen
Economic prospects: Better, worse, or too early to tell? by Scotiabank Market Points
22 min listen
Big Pharma and the Growth and Outlook for Orphan Drugs: Orphan drugs, therapeutics that target small patient populations, have become an enticing area for Big Pharma as companies are attracted to the premium prices, lower development costs, and faster path to market. A new EvaluatePharma report on the Orp... by The Bio Report
20 min listen
Biotech Industry Moves Towards a Patent Cliff: Scrutiny of drug prices around the globe is expected to exert growing pressure on the biopharmaceutical sector. EvaluatePharma, in its recently issued World Preview 2017, Outlook to 2022 says that despite consensus forecasts for worldwide drug sales ... by The Bio Report
15 min listen
CPHI 2022 - Trends, challenges & opportunities: In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses emerging trends and challenges for the life sciences sector live from CPHI Frankfurt 2022,... by Molecule to Market: Inside the outsourcing space
24 min listen
The PR Week: 3.2.2023 - Gemma Hart, Danone: What does it mean to be a B Corp? Danone’s VP of communications and community affairs explains the harder-than-it-looks process and much more on The PR Week. by The PR Week
37 min listen
Vaccine developments knock election news off front page - Scott Martin joins Alpha Trader by Alpha Trader
25 min listen
Biotech’s Record Performance and Looming Threats: Last year, the biotechnology industry set records across the board for financial metrics, a reflection of product success, new drug approvals, and free-flowing investment capital. Despite the record performance, concerns continue about growing pricin... by The Bio Report
19 min listen
The Year in Biotech and What’s Ahead in 2024: Though the year began with a banking crisis and has been marked with layoffs and restructurings, we have managed to avoid a feared recession. It’s been a big year for new drug approvals, M&A activity has been brisk, and biotech stocks have rallie... by The Bio Report
33 min listen
WARC Talks Future of Strategy by The WARC Podcast
39 min listen
Robo advisor Betterment’s CEO says customers are ‘staying the course’ by The Scoop
52 min listen
Sports Betting Buzz, Alibaba And Safe Haven Plays by Wall Street Breakfast
11 min listen
Can the Biotech Industry Stay on Track through Innovative Pricing: The biotechnology industry continued to post record numbers, attract significant investment, and won approval for a solid number of new drugs in 2015. Nevertheless, EY in its new Beyond Borders report warns that there’s a deceleration within the indu... by The Bio Report
22 min listen
Norbert Ore: Lew Weiss and Tim Grady as they interview Norbert Ore, Director of Industry Surveys for Strategas Research Partners. Economic indicators are all moving in a positive direction and there is even a remote possibility that the U.S. could see a 4.0 GDP at le... by Manufacturing Talk Radio
43 min listen
Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard by Business Of Biotech
49 min listen
Pharma and Biotech Daily: From Antitrust Probes to Nanoparticle Innovations by Pharma and BioTech Daily
3 min listen
Why Drug Companies May Soon Become Health Technology Companies: The convergence of technology and life sciences, changing consumer behavior, and increasing pricing pressures on drug and device makers are forcing these companies to rethink business models and how they derive value from their products, according to... by The Bio Report
24 min listen
$1B+ biopharma deals keep values afloat, even amid muted volume by The BioWorld Insider Podcast
28 min listen
Biopharma Buzz: Key Updates in Pharma and Biotech World by Pharma and BioTech Daily
2 min listen
Why the State of Innovation Is Encouraging: Global innovation activity experienced broad gains across industry sectors last year, according to Thompson Reuters newly released 2016 State of Innovation report. We spoke to Anthony Trippe, senior patent analyst for Thomson Reuters about the report... by The Bio Report
37 min listen
Financial Capability Study: Financial Wellbeing During a Global Pandemic: The COVID-19 pandemic disrupted many facets of American life but did not derail a trend toward increasing financial capability. Still, not all Americans are benefiting equally from improvements in financial wellbeing, according to the new FINRA Foundation Financial Capability Study. On this episode we delve into the latest results of this nationwide, triennial study. by FINRA Unscripted
34 min listen
#163 — How to reach product-market fit: BHub, Foodology, and Pomelo at Vamos Latam Summit by Latitud Podcast
39 min listen
51. What’s next in media and marketing?: Jane Ostler and Margo Swadley discuss the trends and changes in media, including TV, radio, social and esports. by Future Proof
28 min listen
October 14th, 2022 by The Top Line
20 min listen
Why Big Pharma Hasn’t Been Able to Fix Its Revenue Gap with M&A by The Bio Report
17 min listen
Why Life Sciences M&A Should Heat up This Year: A surge in merger and acquisition activity in the life sciences is expected this year, according to a new report from EY. The company annual M&A Firepower Report says increased competition, new sources of capital, and the change in U.S. corporate tax... by The Bio Report
19 min listen
It Is a NVIDIA World, We Are Just Living in It (Ep. 74) by Facts vs Feelings with Ryan Detrick & Sonu Varghese
48 min listen

Discover this podcast and so much more

The Year in Biotech So Far and What’s Ahead

The Year in Biotech So Far and What’s Ahead

Description

Titles in the series (100)

More Episodes from The Bio Report

Related podcast episodes